PIP-2 Inhibition-Based Antiviral and Anti-Hyperlipidemic Therapies
OwnerJeffrey S. Glenn, Phillip S. Pang +2inventors
InventorsJeffrey S. Glenn, Phillip S. Pang, Nam-Joon Cho, Choongho Lee
Life of this patent
Estimating the term…
Abstract
Interaction of a specific viral domain with phosphatidylinositol 4,5-bisphosphate (PIP-2) is shown to mediate viral replication. Basic Amino Acid PIP-2 Pincer (BAAPP) domains are described herein, including, without limitation, NS5A protein of HCV, NS4B protein of HCV, poliovirus, and rhinovirus.
Claims14
A method of screening a candidate agent for anti-pathogen activity, the method comprising:
- contacting a pathogen Basic Amino Acid PIP-2 Pincer (BAAPP) domain containing peptide with a phosphatidylinositol 4,5-bisphosphate (PIP-2) in the absence or presence of the candidate agent,
- wherein an agent that specifically interferes with the interaction between the BAAPP domain and PIP-2 is a candidate for anti-pathogen activity.
A method of determining an interaction between a candidate BAAPP domain and PIP-2, the method comprising:
- contacting a candidate peptide with lipid vesicles containing PIP-2, and determining the binding with a quartz crystal microbalance with dissipation (QCM-D) assay.
A method of screening a candidate agent for activity in treating hyperlipidemia, the method comprising:
- contacting a lipoprotein Basic Amino Acid PIP-2 Pincer (BAAPP) domain containing peptide with a phosphatidylinositol 4,5-bisphosphate (PIP-2) in the absence or presence of the candidate agent,
- wherein an agent that specifically interferes with the interaction between the BAAPP domain and PIP-2 is a candidate for activity.
Dependencies are inferred from the claim text.